Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 543322 | NSE Symbol : ALIVUS | ISIN : INE03Q201024 | Industry : Pharmaceuticals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
16-Jan-2025	23-Jan-2025	Quarterly Results	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December 2024. We would wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine months ended December 31, 2024. (As Per BSE Announcement Dated on: 23/01/2025)
17-Oct-2024	24-Oct-2024	Quarterly Results	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended 30th September 2024. Please find attached herewith unaudited Finacial Results for the second quarter and half year ended 30th September 2024 (As per BSE Announcement Dated on 24/10/2024)
18-Jul-2024	25-Jul-2024	Quarterly Results	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the first quarter ended 30th June 2024. Please find attached unaudited financial result for First Quarter ended June 30, 2024 (As Per BSE Announcement Dated on: 25/07/2024)
18-Apr-2024	25-Apr-2024	Accounts	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2024 inter alia to consider and approve Audited Financial Results of the Company for the quarter and year ended March 31 2024. Please Find Attached Audited Financial Results for Quarter and Year ended 31st March 2024 (As Per BSE Announcement Dated on 25/04/2024)
15-Jan-2024	23-Jan-2024	Quarterly Results	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December 2023. As per the ''Code of conduct for Prevention of Insider Trading'' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its ''Designated Persons'' regarding the closure of the trading window from December 31, 2023 to January 25, 2024 (both days inclusive) for the purpose of approval of unaudited financial results for the third quarter and nine months ended December 31, 2023 Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2023. The said meeting of the Board commenced at 03.30 p.m. and concluded at 04:55 p.m. The copy of the said results and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company. (As Per BSE Announcement dated on 23.01.2024)
13-Oct-2023	20-Oct-2023	Quarterly Results	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2023 inter alia to consider and approve Unaudited Financial Results of the Company for the second quarter and half year ended 30th September 2023. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2023. The said meeting of the Board commenced at 10.30 a.m. and concluded at 12.45 p.m. The copy of the said results and Limited Review Report of the Auditors is enclosed herewith. (As per BSE Announcement Dated on 20/10/2023)
04-Oct-2023	09-Oct-2023	Interim Dividend	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/10/2023 inter alia to consider and approve declaration of interim dividend if any for the financial year 2023-24. This is to inform you that the Board of Directors ('Board') of the Company has at its meeting held today i.e. October 09, 2023, inter-alia, declared Interim Equity Dividend for the financial year 2023-24 of Rs. 22.50/- per equity share of Rs. 2 each. As intimated vide our letter dated October 04, 2023, the record date for reckoning the list of shareholders who shall be entitled to receive the said interim dividend shall be Tuesday, October 17, 2023. The interim dividend will be paid to such shareholders on or after October 23, 2023. (As Per BSE Announcement Dated on 09.10.2023)
21-Sep-2023	21-Sep-2023	Others	Disclosure pursuant to the provisions of Regulation 30 of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
13-Jul-2023	21-Jul-2023	Quarterly Results	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30 2023.
19-Apr-2023	27-Apr-2023	Accounts	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/04/2023 inter alia to consider and approve Audited Financial Results of the Company for the quarter and year ended March 31 2023. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31 2023 to April 29 2023 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31 2023. Audited Financial Results for the quarter and year ended March 31, 2023 Re-appointment of Statutory Auditor (As Per BSE Announcement dated on 27.04.2023)
09-Mar-2023	16-Mar-2023	Interim Dividend	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/03/2023 inter alia to consider and approve We have to inform you that pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations 2015 a meeting of the Board of Directors will be held on Thursday March 16 2023 inter alia to consider and declare payment of interim dividend if any on Equity Shares for the financial year 2022-23. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the trading window shall remain closed from March 10 2023 to March 18 2023 (both days inclusive) for above mentioned purpose. This is to inform you that the Board of Directors ('Board') of the Company has at its meeting held today i.e. March 16, 2023, inter-alia, declared Interim Equity Dividend for the financial year 2022-23 of Rs. 21/- per equity share of Rs. 2 each. As intimated vide our letter dated March 14, 2023, the record date for reckoning the list of shareholders who shall be entitled to receive the said interim dividend shall be Friday, March 24, 2023. The interim dividend will be paid to such shareholders on or after March 29, 2023. The Board meeting commenced at 4:30 p.m. and concluded at 6.05 p.m. (As Per BSE Announcement Dated on 16.03.2023)
13-Jan-2023	27-Jan-2023	Quarterly Results	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2023 inter alia to consider and approve We have to inform you that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations 2015 a meeting of the Board of Directors will be held on Friday January 27 2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the Third quarter and Nine months ended December 31 2022. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31 2022 to January 29 2023 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third quarter and Nine months ended December 31 2022. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2022. The said meeting of the Board commenced at 11.00 a.m. and concluded at 12.30 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarklifesciences.com You are requested to take the same on record. (As Per BSE Announcement Dated on 27/01/2023)
14-Oct-2022	21-Oct-2022	Quarterly Results	Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2022 inter alia to consider and approve We have to inform you that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations 2015 a meeting of the Board of Directors will be held on Friday October 21 2022 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2022. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30 2022 to October 23 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30 2022. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2022. The said meeting of the Board commenced at 11.30 a.m. and concluded at 01.10 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarklifesciences.com Outcome of Board Meeting - Changes to the Board (As per BSE Announcement Dated on 21/10/2022)
22-Jul-2022	04-Aug-2022	Quarterly Results	Quarterly Results Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, August 4, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022. Further, as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2022 to August 6, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the first quarter ended June 30, 2022. The above is for your information. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the First Quarter ended June 30, 2022. The said meeting of the Board commenced at 3.30 p.m. and concluded at 6.05 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarklifesciences.com (As Per BSE Announcement Dated 04.08.2022)
13-Apr-2022	20-Apr-2022	Quarterly Results	Audited Results & Final Dividend Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/04/2022 ,inter alia, to consider and approve Audited Financial Results of the Company for the quarter and year ended March 31, 2022 and to consider and recommend final dividend, if any, on Equity Shares for the year ended March 31, 2022. Glenmark Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 20, 2022, inter alia, has recommended final Dividend of Rs. 10.50 per share (face value of Rs. 2/- each) on the Equity Share Capital of the Company for the financial year 2021 - 22 subject to the approval of the Shareholders at the ensuing Annual General Meeting. The Board of Glenmark Life Sciences Limited at its meeting held on April 20, 2022, has, inter alia, considered and approved: 1. The Audited Financial Results for the Year ended March 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The copy of the said results together with Management Discussion & Analysis, Press Release, Auditors Report and Declaration of unmodified opinion are enclosed herewith. These are also being made available on the website of the Company at www.glenmarklifesciences.com. 2. Recommended final Dividend of Rs. 10.50 per share (face value of Rs. 2/- each) on the Equity Share Capital of the Company for the financial year 2021 - 22 subject to the approval of the Shareholders at the ensuing Annual General Meeting. Mr. Bhavesh Pujara has resigned as the Chief Financial Officer of the Company with effect from the close of business hours on April 22, 2022. Consequently, he also ceases to be the Key Managerial Personnel of the Company. On the recommendations of Nomination and Remuneration Committee and approval of the Audit Committee, Board approved the appointment of Mr. Tushar P. Mistry as the Chief Financial Officer (designated as Key Managerial Personnel) of the Company with effect from June 1, 2022. (As Per BSE Announcement Dated on 20.04.2022)

1 2

LOGIN HERE

Alivus Life Sciences Ltd

Board Meeting